UNICREDIT BANK/CALL/NOVO-NORDISK B/1200/0.1/18.09.24 | Market Closed - BOERSE MUENCHEN 20:45:29 07/06/2024 BST | ||
| 0.17 EUR | +13.33% |
|
| Current month | +88.89% | ||
| 1 month | +88.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.17 | +13.33% |
| 06/06/24 | 0.15 | +15.38% |
| 05/06/24 | 0.13 | +62.50% |
| 04/06/24 | 0.08 | +12.68% |
| 03/06/24 | 0.071 | -21.11% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 08:45 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD3KEW |
| ISIN | DE000HD3KEW6 |
| Date issued | 11/03/2024 |
| Strike | 1,200 kr |
| Maturity | 18/09/2024 (102 Days) |
| Parity | 10 : 1 |
| Emission price | 0.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.36 € |
|---|---|
| Lowest since issue | 0.013 € |
| Spread | 0.07 € |
| Spread % | 33.33% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Warrants
- Warrant
